Charles Schwab Investment Management Inc. Boosts Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Charles Schwab Investment Management Inc. grew its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 5.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 328,161 shares of the company’s stock after buying an additional 17,149 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Mirum Pharmaceuticals were worth $12,798,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Candriam S.C.A. acquired a new position in Mirum Pharmaceuticals in the 2nd quarter valued at about $17,384,000. Clearbridge Investments LLC raised its position in shares of Mirum Pharmaceuticals by 165.5% in the second quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock valued at $23,931,000 after buying an additional 436,349 shares during the last quarter. HealthInvest Partners AB lifted its stake in shares of Mirum Pharmaceuticals by 83.9% during the third quarter. HealthInvest Partners AB now owns 138,321 shares of the company’s stock valued at $5,395,000 after buying an additional 63,121 shares during the period. GSA Capital Partners LLP boosted its position in Mirum Pharmaceuticals by 791.7% during the third quarter. GSA Capital Partners LLP now owns 57,985 shares of the company’s stock worth $2,261,000 after acquiring an additional 51,482 shares during the last quarter. Finally, William Blair Investment Management LLC grew its stake in Mirum Pharmaceuticals by 8.1% in the 2nd quarter. William Blair Investment Management LLC now owns 677,939 shares of the company’s stock worth $23,179,000 after acquiring an additional 50,667 shares during the period.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Citigroup increased their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright reiterated a “buy” rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Robert W. Baird lifted their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, Leerink Partners upped their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Ten research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $57.73.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock opened at $44.67 on Monday. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $48.89. The company has a market cap of $2.14 billion, a price-to-earnings ratio of -22.11 and a beta of 1.20. The stock’s 50-day moving average is $41.57 and its 200-day moving average is $38.19.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. During the same quarter last year, the firm posted ($0.57) earnings per share. Mirum Pharmaceuticals’s revenue for the quarter was up 89.4% compared to the same quarter last year. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Insider Activity at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 2,500 shares of the stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $47.10, for a total value of $117,750.00. Following the completion of the sale, the senior vice president now owns 2,426 shares in the company, valued at approximately $114,264.60. This trade represents a 50.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.